Evidence map›Paper›PMID 39311922›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Antibacterial and antibiofilm activities of bacteriocin produced by a new strain of Enterococcus faecalis BDR22.

Bandita Dutta, Debarati Basu, Dibyajit Lahiri, Moupriya Nag, Rina Rani Ray

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bandita DuttaDepartment of Biotechnology, Maulana Abul Kalam Azad University of Technology, Nadia, West Bengal, India.
Debarati BasuDepartment of Biotechnology, Maulana Abul Kalam Azad University of Technology, Nadia, West Bengal, India.
Dibyajit LahiriDepartment of Biotechnology, University of Engineering and Management, Kolkata, India.
Moupriya NagDepartment of Biotechnology, University of Engineering and Management, Kolkata, India.
Rina Rani RayDepartment of Biotechnology, Maulana Abul Kalam Azad University of Technology, Nadia, West Bengal, India. raypumicro@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large number of recalcitrant bacterial pathogens cannot be easily treated by antibiotics due to the existence of biofilm. Hence, an alternative strategy needs to be adopted to remove the biofilm without the development of antibiotic resistance. Bacteriocins, ribosome-mediated proteinaceous toxins, having potential to inhibit the growth of closely or distantly related bacteria. In the present study, after screening a number of sources, a bacteriocin-producing strain, Enterococcus faecalis BDR22, was isolated that showed a significant reduction in the growth of planktonic cells of Gram-positive Staphylococcus aureus, Bacillus subtilis, and Gram-negative Pseudomonas aeruginosa, Escherichia coli, Serratia marcescens, Enterobacter cloacae, and Klebsiella pneumoniae compared to the conventional antibiotic tetracycline. The considerable reduction of the biofilm-forming sessile cells of the test organisms S. aureus (ATCC 23235) and P. aeruginosa (ATCC 10145), with no significant cell revival even after withdrawal of the treatment, was also observed. The extracellular polymeric substance (EPS) content of the biofilm was also reduced, with around 84% total carbohydrate reduction found for both microorganisms. The antibiofilm activities of the strain against test organisms were clearly visible from scanning electron micrographs and confirmed by the changes in functional groups (C-H, -OH, C = C, C-N etc.) of biofilm matrices by Fourier transform infrared spectroscopy (FTIR) analysis. The molecular docking interactions with docking energies ∆G of - 54.40 kcal/mol and - 66.2373 kcal/mol validate the affinity of the bacteriocin towards the biofilm-forming protein, which confirms the competence of the bacteriocin-producing strain to act as an effective antimicrobial and antibiofilm agent, replacing antibiotics.

Indexed as

Anti-Bacterial AgentsBacteriocinsBiofilmsEnterococcus faecalisMicrobial Sensitivity TestsMolecular Docking SimulationAnti-Bacterial AgentsBacteriocinsAntibiofilmBacteriocinEnterococcus faecalis BDR22EPSMolecular dockingTetracycline

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.